Pliant Therapeutics Inc.
06/11/2026 | Press release | Distributed by Public on 06/11/2026 14:52
Proxy Results (Form 8-K)
Item 5.07 Submission of Matters to a Vote of Security Holders.
The 2026 Annual Meeting of Stockholders (the "Annual Meeting") of Pliant Therapeutics, Inc. (the "Company") was held on June 11, 2026. As of April 15, 2026, the record date for the Annual Meeting, there were 61,914,664 shares of the Company's common stock outstanding and entitled to vote at the Annual Meeting. The Company's stockholders voted on the following matters, which are described in detail in the Company's Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 22, 2026: (i) to elect Bernard Coulie, M.D., Ph.D., MBA, Gayle Crowell, and Steve Krognes, MBA, as Class III directors of the Company to serve until the 2029 Annual Meeting of Stockholders and until their successor has been duly elected and qualified, or until his or her earlier death, resignation, or removal ("Proposal No. 1"), (ii) to approve, by non-binding advisory vote, the resolution approving the compensation of the Company's named executive officers ("Proposal No. 2"), and (iii) to ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2026 ("Proposal No. 3"). The vote results detailed below represent final results as certified by the Inspector of Elections.
Proposal No. 1: The Company's stockholders approved the election of each of the aforementioned Class III director nominees to serve until the 2029 Annual Meeting of Stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation, or removal. The voting results are as follows:
| Nominee | For | Withhold | ||||||
|
Bernard Coulie, M.D., Ph.D., MBA
|
18,824,540 | 11,807,308 | ||||||
| Gayle Crowell | 18,186,914 | 12,444,934 | ||||||
|
Steve Krognes, MBA
|
19,299,728 | 11,332,120 | ||||||
The broker non-votes for Proposal No. 1 totaled 11,895,135 shares of common stock.
Proposal No. 2: The Company's stockholders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers. The voting results are as follows:
| For | Against | Abstain | ||||||
| 15,282,788 | 14,572,455 | 776,605 | ||||||
The broker non-votes for Proposal No. 2 totaled 11,895,135 shares of common stock.
Proposal No. 3: The Company's stockholders ratified the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The voting results are as follows:
| For | Against | Abstain | ||||||
| 41,710,604 | 747,140 | 69,239 | ||||||
There were no broker non-votes for Proposal No. 3.
Pliant Therapeutics Inc. published this content on June 11, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on June 11, 2026 at 20:52 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]